Atlas Trials

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT07530094 · RECRUITING

Trial details

NCT number
NCT07530094
Sponsor
Ning Jiang, M.D./Ph.D.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Start date
2025-12-01
Primary completion
2026-12-01
Enrollment
98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.